4.5 Article

Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study

期刊

HEADACHE
卷 52, 期 10, 页码 1456-1470

出版社

WILEY
DOI: 10.1111/j.1526-4610.2012.02223.x

关键词

chronic migraine; episodic migraine; prevalence; headache-related disability; sociodemographics

资金

  1. Allergan, Inc.
  2. Allergan Pharmaceuticals
  3. ENDO Pharmaceuticals
  4. Iroko Pharmaceuticals
  5. Merck, Inc.
  6. MAP Pharmaceuticals
  7. NuPathe
  8. Novartis
  9. Ortho-McNeil
  10. GSK
  11. ENDO
  12. Allergan
  13. MSD
  14. NIH [PO1AG03949, PO1AG027734, RO1AG025119, RO1AG022374-06A2, RO1AG034119, RO1AG12101, K23AG030857, K23NS05140901A1, K23NS47256]
  15. National Headache Foundation
  16. Migraine Research Fund
  17. Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA
  18. Allergan Inc., Irvine, CA, USA

向作者/读者索取更多资源

Objectives. To estimate the prevalence and distribution of chronic migraine (CM) in the US population and compare the age- and sex-specific profiles of headache-related disability in persons with CM and episodic migraine. Background. Global estimates of CM prevalence using various definitions typically range from 1.4% to 2.2%, but the influence of sociodemographic factors has not been completely characterized. Methods. The American Migraine Prevalence and Prevention Study mailed surveys to a sample of 120,000 US households selected to represent the US population. Data on headache frequency, symptoms, sociodemographics, and headache-related disability (using the Migraine Disability Assessment Scale) were obtained. Modified SilbersteinLipton criteria were used to classify CM (meeting International Classification of Headache Disorders, second edition, criteria for migraine with a headache frequency of =15 days over the preceding 3 months). Results. Surveys were returned by 162,756 individuals aged =12 years; 19,189 individuals (11.79%) met International Classification of Headache Disorders, second edition, criteria for migraine (17.27% of females; 5.72% of males), and 0.91% met criteria for CM (1.29% of females; 0.48% of males). Relative to 12 to 17 year olds, the age- and sex-specific prevalence for CM peaked in the 40s at 1.89% (prevalence ratio 4.57; 95% confidence interval 3.13-6.67) for females and 0.79% (prevalence ratio 3.35; 95% confidence interval 1.99-5.63) for males. In univariate and adjusted models, CM prevalence was inversely related to annual household income. Lower income groups had higher rates of CM. Individuals with CM had greater headache-related disability than those with episodic migraine and were more likely to be in the highest Migraine Disability Assessment Scale grade (37.96% vs 9.50%, respectively). Headache-related disability was highest among females with CM compared with males. CM represented 7.68% of migraine cases overall, and the proportion generally increased with age. Conclusions. In the US population, the prevalence of CM was nearly 1%. In adjusted models, CM prevalence was highest among females, in mid-life, and in households with the lowest annual income. Severe headache-related disability was more common among persons with CM and most common among females with CM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据